Physician profile
Randall Jacobs
NPI 1093798316
$9,865.62
in general payments reported to CMS, 2019-2025
37 companies · $596 in 2025
The $596 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,776 · 2020: $569 · 2021: $1,309 · 2022: $2,129 · 2023: $2,328 · 2024: $1,159 · 2025: $596.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,083.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,082.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,221.11 | 2019-2025 | |
| Janssen Biotech, INC. | $1,170.59 | 2019-2025 | Stelara, Tremfya, Simponi |
| Takeda Pharmaceuticals U.S.A., INC. | $932.46 | 2019-2025 | Entyvio |
| Celgene Corporation | $745.49 | 2021-2023 | Zeposia |
| Genzyme Corporation | $500.12 | 2022-2024 | |
| Gilead Sciences, INC. | $465.98 | 2019-2023 | Epclusa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $452.90 | 2019-2023 | Trulance |
| Regeneron Healthcare Solutions, INC. | $382.31 | 2022-2024 | Dupixent |
| Ironwood Pharmaceuticals, INC | $315.10 | 2020-2024 | Linzess |
| Phathom Pharmaceuticals, INC. | $278.15 | 2024 | Voquezna |
| Pfizer INC. | $257.05 | 2019-2023 | |
| Ardelyx, INC. | $256.59 | 2022-2024 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $246.78 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $159.27 | 2025 | Rezdiffra |
| Janssen Scientific Affairs, LLC | $145.10 | 2021-2025 | Tremfya, Stelara |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $137.46 | 2022-2023 | Amjevita, Avsola |
| Ferring Pharmaceuticals INC. | $136.14 | 2019-2023 | Rebyota |
| Galderma Laboratories, L.P. | $134.08 | 2025 | Nemluvio |
| Nestle Healthcare Nutrition INC. | $130.24 | 2021-2023 | |
| Dova Pharmaceuticals | $122.50 | 2019 | |
| Merck Sharp & Dohme LLC | $98.94 | 2019-2022 | |
| Intercept Pharmaceuticals, INC. | $71.26 | 2021-2022 | |
| Braintree Laboratories, INC. | $55.14 | 2021-2022 | |
| Daiichi Sankyo INC. | $47.73 | 2019-2023 | Injectafer |
| Organon LLC | $45.92 | 2022-2023 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $43.28 | 2023 | Idacio |
| Qol Medical, LLC | $42.68 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $37.94 | 2023 | Andexxa |
| Welch Allyn | $34.47 | 2019 | |
| Ucb, INC. | $33.48 | 2019 | |
| Alnylam Pharmaceuticals INC. | $33.26 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $31.12 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.40 | 2023 | Cyltezo |
| Sandoz INC. | $23.00 | 2023 | Hyrimoz |
| Romark Laboratories, Lc | $22.27 | 2019 | |
| Lilly USA, LLC | $17.38 | 2024 | Omvoh |
| Allergan, INC. | $12.93 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Randall Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.